{"id":"continuation-of-oral-anticoagulants","safety":{"commonSideEffects":[{"rate":"1-5% for major bleeding depending on indication and agent","effect":"Bleeding (major and minor)"},{"rate":"1-3%","effect":"Gastrointestinal bleeding"},{"rate":"0.5-1%","effect":"Intracranial hemorrhage"},{"rate":"5-10%","effect":"Dyspepsia"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oral anticoagulants work through two main classes: vitamin K antagonists (e.g., warfarin) that inhibit factors II, VII, IX, and X, and direct oral anticoagulants (DOACs) that directly inhibit factor Xa or thrombin (factor IIa). Both mechanisms reduce the ability of blood to clot, thereby preventing pathological thrombus formation in conditions prone to thromboembolism.","oneSentence":"Oral anticoagulants prevent blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:55.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (DVT/PE) prevention and treatment"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Post-surgical thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT07496281","phase":"PHASE4","title":"OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2027-03-01","conditions":"Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent","enrollment":2},{"nctId":"NCT04394546","phase":"NA","title":"CHAMPION-AF Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2020-10-15","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3000},{"nctId":"NCT04226547","phase":"NA","title":"Amplatzer Amulet LAAO vs. NOAC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2020-07-07","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":2650},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT04437303","phase":"PHASE4","title":"Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2020-11-25","conditions":"Aortic Valve Disease, Aortic Valve Stenosis, Stroke","enrollment":858},{"nctId":"NCT06216769","phase":"NA","title":"Pill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-02-01","conditions":"Atrial Fibrillation","enrollment":400},{"nctId":"NCT03702582","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-04-30","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":100},{"nctId":"NCT03437356","phase":"NA","title":"Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drugs in Persistent Atrial Fibrillation","status":"COMPLETED","sponsor":"AZ Sint-Jan AV","startDate":"2018-02-26","conditions":"Atrial Fibrillation","enrollment":210},{"nctId":"NCT02885545","phase":"PHASE4","title":"The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial","status":"WITHDRAWN","sponsor":"Population Health Research Institute","startDate":"2016-09","conditions":"Chronic Kidney Disease, Acute Bleeding, Cerebrovascular Stroke","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Continuation of oral anticoagulants","genericName":"Continuation of oral anticoagulants","companyName":"St. Antonius Hospital","companyId":"st-antonius-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral anticoagulants prevent blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) prevention and treatment, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}